From Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs:

Nura Bio CEO Alpna Seth

Nura Bio CEO Alpna Seth—

Headshot of Alpna Seth courtesy of Nura Bio

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX

From Our Editors · Podcast
Xcelerating Life Sciences Philadelphia: The Highlights Podcast
Becoming the Cell & Gene Therapy Hub

Xconomy on Demand

We offer a number of ways to subscribe for free!